Plus   Neg

AIG To Relocate Global HQ In New York City To 1271 Avenue Of Americas - Quick Facts

Insurer American International Group, Inc. (AIG) announced Tuesday that it will relocate its global headquarters in New York City to 1271 Avenue of the Americas located in Rockefeller Center, where it will occupy 8 floors and 325,000 square feet.

The Company will also consolidate its remaining New York City area footprint into approximately 450,000 square feet divided between two new locations at 28 Liberty Street building in Lower Manhattan and 30 Hudson Street located on the waterfront of Jersey City, New Jersey. The Company plans to move into the three new offices in 2021.

By optimizing and modernizing our New York City area real estate footprint, AIG will align its workplaces with the objectives of AIG 200, its global, multi-year effort to position AIG for the future. The offices will be designed in three Class A buildings that will allow its teams to work more effectively and collaboratively with high-quality infrastructure.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Despite the coronavirus pandemic, retailers are prepared for an early start to the holiday shopping season by offering discounts earlier so that consumers can buy and receive the gifts they want in time, the National Retail Federation or NRF said. The NRF also said it is launching a nationwide consumer education campaign called "New Holiday Traditions". Facebook (FB) has revealed new messaging features for Instagram, which will make it easier for users to stay in touch with others across Facebook's family of apps. The main change is that people using the Messenger app can now reach Instagram users, and vice versa. The users can control where they receive... Regeneron Pharmaceuticals, Inc. announced positive first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cocktail REGN-COV2 in COVID-19 patients. REGN-COV2 rapidly reduced viral load and associated symptoms in infected COVID-19 patients. The company said it plans rapidly to discuss results with regulatory authorities.
Follow RTT